Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have received an average rating of "Buy" from the six ratings firms that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $6.33.

Several research firms have commented on CNTX. JMP Securities started coverage on shares of Context Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $4.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Context Therapeutics in a research report on Monday, September 23rd. Finally, D. Boral Capital began coverage on Context Therapeutics in a research report on Monday, November 25th. They set a "buy" rating and a $9.00 price objective on the stock.

Context Therapeutics Price Performance

Shares of CNTX stock traded up $0.12 during trading hours on Wednesday, hitting $1.21. The stock had a trading volume of 783,242 shares, compared to its average volume of 342,874. The stock has a market capitalization of $90.75 million, a price-to-earnings ratio of -1.33 and a beta of 2.10. Context Therapeutics has a one year low of $0.89 and a one year high of $2.75. The stock's 50-day moving average price is $1.54 and its two-hundred day moving average price is $1.94.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.11). As a group, equities research analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors have recently modified their holdings of CNTX. Franklin Resources Inc. purchased a new stake in Context Therapeutics in the third quarter worth about $3,689,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Context Therapeutics in the 3rd quarter worth approximately $89,000. State Street Corp boosted its stake in shares of Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company's stock valued at $219,000 after purchasing an additional 19,800 shares in the last quarter. Nantahala Capital Management LLC bought a new position in Context Therapeutics in the second quarter worth approximately $3,881,000. Finally, Driehaus Capital Management LLC purchased a new stake in Context Therapeutics during the second quarter worth $4,527,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.